Pfizer gets some encouraging PhIII news on a franchise savior, but is a dosing advantage worth the $295M upfront?
Close to 3 years after Opko tried to defend itself as shares tumbled on the news that its long-acting growth hormone had failed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
